Previous Close | 14.09 |
Open | 14.06 |
Bid | 14.25 x 800 |
Ask | 14.27 x 1000 |
Day's Range | 13.98 - 14.33 |
52 Week Range | 12.24 - 28.06 |
Volume | |
Avg. Volume | 2,644,857 |
Market Cap | 2.311B |
Beta (5Y Monthly) | 0.67 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for ACAD
An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.
A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis. The drug, Nuplazid, is already indicated for Parkinson's-related psychosis. Acadia tried and failed last year to get another FDA approval for Alzheimer's psychosis. Related: Acadia Stock Drops After FDA CRL For Pimavanserin Application In Hallucinations and Dementia-Related Psychosis. "We are disappoin
Shares of Acadia Pharmaceuticals Inc. were still down 30.5% in premarket trading on Tuesday, days after a Food and Drug Administration advisory committee voted against approval of the company's treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The committee on Friday voted 9-3 that the benefits of pimavanserin do not outweigh the risks. The FDA, which is not required to follow the advice of the committee but often does, is expected to decide whether to app